Zymeworks ZW220 TOPO1i ADC 2023 World ADC Conference

Zymeworks presented ZW220, an internally discovered, first-in-class NaPi2b-targeting antibody-drug conjugate utilizing a novel topoisomerase-1 inhibitor payload with strong bystander activity for treating NaPi2b-expressing solid tumors. The presentation detailed ZW220's design, payload optimization, and conjugation chemistry through stochastic cysteine conjugation with a traceless peptide linker.